Mouse Anti-CDCA3 Recombinant Antibody (3B9) (CBMAB-C5760-LY)

Li, K., Li, S., Tang, S., Zhang, M., Ma, Z., Wang, Q., & Chen, F. (2021). KIF22 promotes bladder cancer progression by activating the expression of CDCA3. International journal of molecular medicine, 48(6), 1-13.

Sahin, K. B., Shah, E. T., Ferguson, G. P., Molloy, C., Kalita-de Croft, P., Hayes, S. A., ... & Adams, M. N. (2021). Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancer. Cancers, 13(18), 4651.

Yu, J., Hua, R., Zhang, Y., Tao, R., Wang, Q., & Ni, Q. (2020). DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter. Journal of cellular biochemistry, 121(1), 142-151.

Zhang, Y., Yin, W., Cao, W., Chen, P., Bian, L., & Ni, Q. (2019). CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer. Oncology reports, 41(4), 2471-2481.

Bi, L., Zhou, B., Li, H., He, L., Wang, C., Wang, Z., ... & Gao, S. (2018). A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. BMC cancer, 18(1), 1-17.

Qian, W., Zhang, Z., Peng, W., Li, J., Gu, Q., Ji, D., ... & Sun, Y. (2018). CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. International journal of oncology, 53(5), 2021-2033.

Zhang, W., Lu, Y., Li, X., Zhang, J., Zheng, L., Zhang, W., ... & Li, X. (2018). CDCA3 promotes cell proliferation by activating the NF-κB/cyclin D1 signaling pathway in colorectal cancer. Biochemical and biophysical research communications, 500(2), 196-203.

Phan, N. N., Wang, C. Y., Li, K. L., Chen, C. F., Chiao, C. C., Yu, H. G., ... & Lin, Y. C. (2018). Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient. Oncotarget, 9(6), 6977.

Adams, M. N., Burgess, J. T., He, Y., Gately, K., Snell, C., Zhang, S. D., ... & O’Byrne, K. J. (2017). Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non–small cell lung cancer. Journal of Thoracic Oncology, 12(7), 1071-1084.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols